Serial No.: 10/560,558 **PATENT**

Response to Restriction Requirement WSGR Reference No. 30915-701.831

LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in this application.

1. (Currently Amended) A composition comprising

between about 20 to about 26% Brassica oleracea;

between about 30 to about 36% Daucus carota;

between about 22 to about 28% Apium L.;

between about 0.1 to about 1.5% Petroselinum crispum;

between about 9 to about 15% Spinacia oleracea L;

between about 6 to about 12% Beta vulgaris;

between about 0.1 to about 1.5% aloe vera; and

between about 0.1 to 1.5% honey.

2-6. (Canceled)

7. (Original) A dietary supplement comprising an effective amount of a claim 1.

8. (Original) The composition of claims 1, wherein the form of the composition is selected from the group consisting of an orally administered form, and an injectable form.

9. (Original) The composition of claim 8, wherein the composition is in the orally administered form and the orally administrable form is selected from a group consisting of a juice, a tablet, a powder, a suspension, an emulsion, a capsule, a granule, a troche, a pill, a liquid, a spirit, a syrup, and a limonade.

10. (Original) The composition of claim 8, wherein the composition is in the injectable form and the injectable form is selected from the group consisting of a liquid, a suspension, and a solution.

3948643 1.DOC

Serial No.: 10/560,558 PATENT

Response to Restriction Requirement WSGR Reference No. 30915-701.831

11. (Canceled)

12. (Original) A pharmaceutical composition comprising a pharmaceutically effective amount

of the composition of claim 1.

13. (Original) The pharmaceutical composition of claim 7, wherein the form of the

composition is selected from a group consisting of an orally administered form and an

injectable form.

14. (Original) The pharmaceutical composition of claim 13, wherein the composition is in the

orally administered form and the orally administrable form is selected from a group consisting

of a juice, a tablet, a powder, a suspension, an emulsion, a capsule, a granule, a troche, a pill, a

liquid, a spirit, a syrup, and a limonade.

15. (Original) The pharmaceutical composition of claim 13, wherein the composition is in the

injectable form and the injectable form is selected from the group consisting of a liquid, a

suspension, and a solution.

16. (Canceled)

17. (Original) The composition of claim 1, wherein the composition is administered as a

dietary supplement.

18. (Withdrawn) A method of administering the composition of claim 1, wherein the

composition is administered over a period of time to a patient having liver cancer.

19. (Withdrawn) A method of administering the composition of claim 1, wherein the

composition is administered over a period of time to a patient and the liver regenerates.

20. (Withdrawn) A method of administering the composition of claim 1, wherein the

3948643_1.DOC

-3-

Serial No.: 10/560,558 PATENT

Response to Restriction Requirement WSGR Reference No. 30915-701.831

composition is administered over a period of time to a patient for the prevention of liver cancer.

21-22. (Canceled)

23. (Withdrawn) A method of treatment of liver cancer, comprising administering the composition of claim 1 in combination with other known, standard or experimental treatment

protocols for liver cancer.

24. (Withdrawn) A method of treatment of liver cancer, comprising administering the

composition of claim 1 to reduce the size of inoperable liver cancers.

25. (Withdrawn) A method of treatment of liver damage, comprising administering the

composition of claim 1 to aide in liver regeneration.

26. (Withdrawn) A method for treatment of a disorder of the hepatobiliary system, comprising

administering the composition of claim 1.

27-28. (Canceled)

29. (Withdrawn) A method for the treatment of cancer comprising oral administration of the

composition of claim 1 with other known standard or experimental treatment protocols.

30-31. (Canceled)

32. (Original) The pharmaceutical composition of claim 12 comprising, a pharmaceutically

acceptable carrier.

33. (Withdrawn) A method of administering of the composition of claim 8, wherein the

composition is administered to a patient and the patient has cirrhosis.

3948643_1.DOC

-4-

PATENT

WSGR Reference No. 30915-701.831

Serial No.: 10/560,558 Response to Restriction Requirement

34. (Withdrawn) A method of administration of the composition of claim 8, wherein the

composition is administered to a patient and the patient has hepatitis.

35. (New) A composition mixture comprising

a Brassica oleracea component, said Brassica oleracea component comprises about 1031.48

mg potassium;

a Apium graveolens component, said Apium graveolens component comprises about 979.8 mg

potassium;

a Spinacia oleracea component, said Spinacia oleracea component comprises about 885.1 mg

potassium;

a Daucus carota component, said Daucus carota component comprises about 1043 mg

potassium;

a Beta vulgaris component, said Beta vulgaris component comprises about 347.06 mg

potassium;

a Petroselinum crispum component, said Petroselinum crispum component comprises about

89.46 mg potassium; and

a honey component, said honey component comprises about 11 mg potassium.

36. (New) A composition mixture comprising

a Brassica oleracea component, said Brassica oleracea component comprises about 144.6 mg

calcium;

a Apium graveolens component, said Apium graveolens component comprises about 136.3 mg

calcium;

a Spinacia oleracea component, said Spinacia oleracea component comprises about 159.0 mg

calcium;

a Daucus carota component, said Daucus carota component comprises about 119.2 mg

calcium;

a Beta vulgaris component, said Beta vulgaris component comprises about 18.76 mg calcium;

a Petroselinum crispum component, said Petroselinum crispum component comprises about

21.3 mg calcium; and

a honey component, said honey component comprises about 1 mg calcium.

3948643_1.DOC

-5-